Technology
Choose a subcategory:
About Regenicin Regenicin, Inc. is a development-stage company focusing on next-generation tissue-engineered skin substitutes to restore the qualities of healthy human skin.
Neptune Technologies & Bioressources Inc. Andre Godin, Vice President, Finance & Administration 450-687- 2262 a. godin@ neptunebiotech. com www.neptunebiotech. com Acasti Pharma Inc. Tina Sampalis, President 450-686- 4555 t. sampalis@ acast
Nidec Corporation Announces Notice of Determination of the Terms of Issuance of Euro Yen Convertible
KYOTO, Japan, Sept. 2, 2010 ( GLOBE NEWSWIRE)- Nidec Corporation ( the " Company") announced today that it had determined the terms of the issuance with regard to the issuance of the Euro Yen Convertible-Bonds-Type Bonds with Stock Acquisit
Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
These risks and uncertainties include, but are not limited to: the risk that we may be unable to further identify, develop and achieve commercial success for new products and technologies; the risk that we may be unable to discover drugs th
Reports include: REGULATORY & COMPLIANCE NEWS Friction Factor- market-maker surveillance system tracking market-makers in all stocks to determine Price Friction and compliance with new " Fair Market-Making Requirements" RegSHO Naked Shorts-
These risks, including those related to inability to comply with NASDAQ's continued listing requirements; the generally unstable nature of current economic and financial market conditions; the results of discovery research and pre-clinical
Neptune Technologies & Bioressources Inc. Andre Godin, Vice President, Finance & Administration 450-687- 2262 a. godin@ neptunebiotech. com www.neptunebiotech. com Acasti Pharma Inc. Tina Sampalis, President 450-686- 4555 t. sampalis@ acast
Mr. Yu plans to implement immediately the following strategic initiatives:- Identify strategic acquisition and investment opportunities in high-growth industries- Build a results-oriented management team- Execute strategic transactions inte
SAN DIEGO, Sept. 2, 2010 ( GLOBE NEWSWIRE)- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange, today announced that Shintaro Asako, Chi
( D) Early redemption on delisting of the shares: ( a) If ( i) any offer is made by a party or parties ( the " Offeror") other than the Company in accordance with the Financial Instruments and Exchange Law to all holders of the shares of co
In particular, the risks and uncertainties include, among other things: risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured; the risk that we will not achieve the anticipated benefits of